Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

British Journal of Cancer

Volumn 79, Issue 7-8, 1999, Pages 1190-1198

  De Witte, J H ^a   Sweep, C G J ^a   Klijn, J G M ^b   Grebenschikov, N ^a   Peters, H A ^b   Look, M P ^b   Van Tienoven, Th H ^a   Heuvel, J J T M ^a   Van Putten, W L J ^b   Benraad, Th J ^a   Foekens, J A ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Cytosol; Enzyme linked immunosorbent assay; Plasminogen activator inhibitor; Prognostic impact; Urokinase type plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CYTOSOL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033016406     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690191     Document Type: Article

References (29)

1. Andreasen PA, Georg B, Lund LR, Riccio A and Stacey SN (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68: 1-19
2. Andreasen PA, Kjoller L, Christensen L and Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
3. Benraad ThJ, Geurts-Moespot J, Grøndahl-Hansen J, Schmitt M. Heuvel JJTM, de Witte JH, Foekens JA, Leake RE, Brünner N and Sweep CGJ (1996) Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer 32A: 1371-1381
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Annal Biochem 72: 248-254
5. Chapman HA (1997) Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 9: 714-724
6. De Witte H, Pappot H, Brünner N, Grøndahl-Hansen J, Høyer-Hansen G, Behrendt N, Guldhammer-Skov B, Sweep CGJ, Benraad ThJ and Danø K (1997) ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts. Int J Cancer 72: 416-423
7. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266
8. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M and Pyke C (1994) The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8(suppl. 1): 189-203
9. Duffy MJ (1992) The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10: 145-155
10. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618
11. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ and Andreasen PA (1990) Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6929
12. EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second EORTC workshop, held on 16-17 March 1979, in The Netherlands Cancer Institute. Eur J Cancer 16: 1513-1515
13. Fernö M, Bendahl P-O, Borg Å, Brundell J, Hirschberg L, Olsson H and Killander D (1996) Urokinase plasminogen activator, a strong independent prognostic-factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793-801
14. Foekens JA, Portengen H, van Putten WLJ, Peters HA, Krijnen HLJM, Alexieva-Figusch J and Klijn JGM (1989) Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 49: 5823-5228
15. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
16. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Jänicke F and Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 6148-1658
17. Grebenschikov N. Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F and Benraad T (1997) A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1 ) in breast tumor cytosols. Int J Biol Markers 12: 6-14
18. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
19. Jänicke F, Schmitt M, Ulm K, Gössner W and Graeff H (1989) Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 8670: 1049
20. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W and Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
21. Jänicke F, Schmitt M and Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type-1 inhibitor in breast cancer. Semin Thromb Hemostas 17: 303-312
22. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
23. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H (1994a) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530
24. Jänicke F, Thomssen C, Pache L, Schmitt M and Graeff H (1994b) Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In Prospects in Diagnosis and Treatment of Breast Cancer, Schmitt M, Graeff H and Kindermann G (eds), pp. 207-218. Elsevier Publishers: Amsterdam
25. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-181
26. Liotta LA, Thorgeirsson UP and Garbisa S (1982) Role of collagenases in tumor cell invasion, tissue degradation, and cancer. Cancer Metastasis Rev 1: 277-297
27. Mignatli P and Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195
28. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F and Graeff H (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296
29. Spyratos F, Martin P-M, Hacène K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, Le Doussal V, Tubiana-Hulin M and Brunet M (1992) Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272